Compounds and methods for treating chemotherapy-induced pain

Inhibiting AAK1 with specific inhibitors addresses the lack of effective CIPN treatments by reducing chemotherapy-induced pain and neuropathy, enabling continued chemotherapy while minimizing side effects.

WO2025175003A1 Publication Date: 2025-08-21LEXICON PHARMACEUTICALS INC
7 Cites 0 Cited by

Patent Information

Application Number
PCT/US2025/015790
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-02-15
Filing Date
2025-02-13
Publication Date
2025-08-21

AI Technical Summary

Technical Problem

Current treatments for chemotherapy-induced peripheral neuropathy (CIPN) are inadequate, with no approved agents for prevention or effective management, leading to significant quality of life impairments and potential need to discontinue chemotherapy.

Method used

Inhibition of adaptor associated kinase 1 (AAK1) using a therapeutically or prophylactically effective amount of an AAK1 inhibitor, such as (S)-l-((2',6-bis(difluoromethyl)-[2,4'-bipyridin]-5-yl)oxy)-2,4-dimethylpentan-2-amine or its pharmaceutically acceptable salts, administered alone or with chemotherapeutic agents like oxaliplatin, to treat, manage, or prevent CIPN.

Benefits of technology

Reduces chemotherapy-induced pain and minimizes neuropathy, allowing continued chemotherapy without exacerbating symptoms, thereby improving patient quality of life and treatment efficacy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Disclosed herein are methods and compositions for treating, managing, and preventing chemotherapy-induced pain in a patient in need thereof. Particular methods and compositions utilize an adaptor associated kinase 1 inhibitor of Formula (I).
Need to check novelty before this filing date? Find Prior Art